Benchmark Research’s Austin, Texas location was recognized as Best Clinical Trial Site at the 2012 Vaccine Industry Excellence (ViE) Awards, held during the Annual World Vaccine Congress.

Benchmark Research is a network of therapeutically diverse, dedicated, multi-therapeutic research centers that specializes in vaccine research. The panel of judges commended Benchmark Research Austin for exceeding enrollment timelines for all studies and for being the first site to complete enrollment in three of the seven trials within the judging period.

“Having two Benchmark Research sites considered for the inaugural Best Clinical Trial Site category is a testament to the efforts of the entire Benchmark team, not only those nominated sites. I am very proud of what each of our sites accomplished over the last year, and I'm especially honored to have Austin recognized as the top site in this category,” said Mark Lacy, co-founder and CEO of Benchmark Research.

“It is truly an honor for Benchmark Research to be recognized as Best Clinical Trial Site. We have committed substantial time and resources in developing our specialty as industry-leading vaccine sites, and being recognized with this ViE award represents a culmination of those efforts,” added Scott Barrett, Benchmark Research co-founder and COO.

Benchmark Research offers clients access to nearly 60,000 patients in its research database and nearly 16 million potential patients in Sacramento and San Francisco, California; New Orleans, Louisiana; and Austin, Fort Worth and San Angelo, Texas. Benchmark’s geographic and demographic diversity allows it to meet and exceed enrollment projections. Currently, Benchmark works with more than 40 Principal Investigators and supports a range of therapeutic areas.